Cargando…
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
The success of the first licensed mRNA-based vaccines against COVID-19 has created a widespread interest on mRNA technology for vaccinology. As expected, the number of mRNA vaccines in preclinical and clinical development increased exponentially since 2020, including numerous improvements in mRNA fo...
Autores principales: | Matarazzo, Laura, Bettencourt, Paulo J. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166207/ https://www.ncbi.nlm.nih.gov/pubmed/37168860 http://dx.doi.org/10.3389/fimmu.2023.1172691 |
Ejemplares similares
-
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
por: Wang, Bolin, et al.
Publicado: (2023) -
Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens
por: Bettencourt, Paulo
Publicado: (2020) -
mRNA vaccines for cancer immunotherapy
por: Vishweshwaraiah, Yashavantha L., et al.
Publicado: (2022) -
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
por: Deng, Zhuoya, et al.
Publicado: (2022) -
Advances in mRNA Vaccines for Infectious Diseases
por: Zhang, Cuiling, et al.
Publicado: (2019)